A Phase 4 interventional study of Apixaban and No Oral Anticoagulation Strategy in Intracerebral Hemorrhage, Atrial Fibrillation (AF) and Ischemia Stroke, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.
Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 8th largest by planned enrollment of the 77 interventional ones that give a count, is one of 15 that started in 2026, is one of 4 in phase 4, reaches primary completion later than 59 of the 61 other live ones, and was the 114th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Jiangsu Province (Suqian) Hospital · Sites in China
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Yanyan Gong · Sites in China
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 4
First in 2005; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 852 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 180 across the 77 interventional studies, 664 across the 46 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 123 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Cerebral Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT06688162Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S) | 2026-11-30 |
| NCT06688201Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L) | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 123 studies in Cerebral Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to evaluate the efficacy and safety of oral anticoagulation with apixaban in patients with non-valvular atrial fibrillation, ischemic stroke, and a history of spontaneous, non-traumatic deep intracerebral hemorrhage. Eligible intracerebral hemorrhage is located in the basal ganglia, thalamus, pons, or deep cerebellum and is non-lobar and non-intraventricular. Participants will be randomized in a 1:1 ratio to apixaban or a no-oral-anticoagulation strategy. Participants assigned to apixaban will receive 5 mg twice daily, with dose reduction according to the approved prescribing information when indicated. Participants assigned to no oral anticoagulation may receive single antiplatelet therapy or no antithrombotic therapy at the discretion of the treating physician. Participants will be followed for at least 6 months and up to 36 months. The primary outcome is the first occurrence of recurrent ischemic stroke or recurrent intracerebral hemorrhage, whichever occurs first.
The criteria were revised on the registry on Oct 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the anticoagulation group will receive oral apixaban 5 mg twice daily. Dose reduction will be performed according to the approved prescribing information when indicated.
Drug: Apixaban
Participants will not receive oral anticoagulation. Single antiplatelet therapy, such as aspirin or clopidogrel, or no antithrombotic therapy is permitted at the discretion of the treating physician according to clinical guidelines and individual patient characteristics.
Other: No Oral Anticoagulation Strategy
Oral apixaban 5 mg twice daily, with dose reduction according to the approved prescribing information when indicated.
No oral anticoagulation; single antiplatelet therapy or no antithrombotic therapy is permitted at the discretion of the treating physician.
Time to First Occurrence of Recurrent Ischemic Stroke or Recurrent Intracerebral Hemorrhage
Time from randomization to the first occurrence of recurrent ischemic stroke or recurrent intracerebral hemorrhage, whichever occurs first.
Time frame: From randomization to the first qualifying event or the end of follow-up, up to 36 months
First Recurrent Ischemic Stroke
Occurrence of the first recurrent ischemic stroke during follow-up.
Time frame: Up to 36 months
First Recurrent Intracerebral Hemorrhage
Occurrence of the first recurrent intracerebral hemorrhage during follow-up.
Time frame: Up to 36 months
Vascular Death
Death due to a vascular cause during follow-up.
Time frame: Up to 36 months
All-Cause Death
Death from any cause during follow-up.
Time frame: Up to 36 months
Major Bleeding Events
Major bleeding events defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.
Time frame: Up to 36 months
Modified Rankin Scale (mRS) Score Distribution
Distribution of scores on the modified Rankin Scale, ranging from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability.
Time frame: 6, 12, 24, and 36 months after randomization
Clinically Relevant Non-Major Bleeding
Bleeding that does not meet the ISTH criteria for major bleeding but results in hospitalization, medical intervention, or discontinuation of study treatment.
Time frame: Up to 36 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2031, 60 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jun 2026 → Oct 2026, primary completion Jun 2029 → Nov 2031 and completion Sep 2029 → Feb 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban
Second Affiliated Hospital, Zhejiang University, School of Medicine →